2 lines
No EOL
1.2 KiB
Text
2 lines
No EOL
1.2 KiB
Text
"Project #","Project Title","Research Focus Area","Research Program","Administering IC(s)",Institution(s),Investigator(s),Location(s),"Year Awarded",Summary
|
|
1R43NS125643-01,"Development of an intranasal, direct to nerve treatment for headache disorders","Cross-Cutting Research","Small Business Programs",NINDS,"Olfax, LLC","BECKWITH, JONATHAN G (contact); COOK, JASON T","Asheville, NC",2022,"About 14% of U.S. adults report experiencing migraine symptoms within any given 3-month period, making it the second most disabling illness in the world. Nonspecific pain medications used in migraine (e.g., acetaminophen, nonsteroidal inflammatory drugs, opioids) are often not effective for severe migraine symptoms or cause significant adverse effects. A research team of migraine care specialists, device and drug developers, and clinical research specialists has created a technology for accurately delivering self-administered migraine medication to the upper nasal cavity. The technology enables development of a self-administered therapy to provide rapid pain relief without harsh and addictive side effects of existing migraine medications. This project will establish efficacy and evaluate commercial design feasibility for this treatment." |